Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Rituximab, a chimeric anti-CD20 monoclonal antibody, is used to deplete mature B cells and reduce the production of autoantibodies. About 98.6% patients exhibited depletion of peripheral blood CD19 + ...

Auto-immune and inflammatory diseases are heterogenous in their clinical manifestations and prognosis, even among individuals presenting with the same pathology. Understanding the immunological ...

Objective The present study aimed to provide a comprehensive evaluation of the postmarketing safety of belimumab based on the Food and Drug Administration Adverse Event Reporting System (FAERS) ...

科济药业-B（02171）早盘持续走高，股价上涨9.62%，现报10.14港元，成交额7102.37万港元。 科济药业今早宣布，公司自主研发的 ...

Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Institute for Advanced Optics, Hunan Institute of Science and Technology, Yueyang, Hunan 414006, China School of Information Science & Technology, Hunan Institute of Science and Technology, Yueyang, ...

今日，先博生物宣布，其自主研发的通用型异体CD19 CAR-NK药物SNC103已成功完成两例一期临床给药，该疗法针对复发和/或难治性 ...

Other B-cell depleting antibodies include anti-CD19 antibodies ... Accordingly, anti-BAFF antibodies (belimumab) or BAFF-R–Ig provide selective BAFF blockade, whereas a TACI decoy receptor ...